206 related articles for article (PubMed ID: 25043303)
41. The tyrosine kinase Abl is required for Src-transforming activity in mouse fibroblasts and human breast cancer cells.
Sirvent A; Boureux A; Simon V; Leroy C; Roche S
Oncogene; 2007 Nov; 26(52):7313-23. PubMed ID: 17533370
[TBL] [Abstract][Full Text] [Related]
42. The EphB4 receptor suppresses breast cancer cell tumorigenicity through an Abl-Crk pathway.
Noren NK; Foos G; Hauser CA; Pasquale EB
Nat Cell Biol; 2006 Aug; 8(8):815-25. PubMed ID: 16862147
[TBL] [Abstract][Full Text] [Related]
43. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
44. A crucial role in cell spreading for the interaction of Abl PxxP motifs with Crk and Nck adaptors.
Antoku S; Saksela K; Rivera GM; Mayer BJ
J Cell Sci; 2008 Sep; 121(Pt 18):3071-82. PubMed ID: 18768933
[TBL] [Abstract][Full Text] [Related]
45. Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.
Bhat A; Johnson KJ; Oda T; Corbin AS; Druker BJ
J Biol Chem; 1998 Nov; 273(48):32360-8. PubMed ID: 9822717
[TBL] [Abstract][Full Text] [Related]
46. Crk adaptor proteins regulate CD3ΞΆ chain phosphorylation and TCR/CD3 down-modulation in activated T cells.
Dong G; Kalifa R; Nath PR; Babichev Y; Gelkop S; Isakov N
Cell Signal; 2017 Aug; 36():117-126. PubMed ID: 28465009
[TBL] [Abstract][Full Text] [Related]
47. The leukaemic oncoproteins Bcr-Abl and Tel-Abl (ETV6/Abl) have altered substrate preferences and activate similar intracellular signalling pathways.
Voss J; Posern G; Hannemann JR; Wiedemann LM; Turhan AG; Poirel H; Bernard OA; Adermann K; Kardinal C; Feller SM
Oncogene; 2000 Mar; 19(13):1684-90. PubMed ID: 10763825
[TBL] [Abstract][Full Text] [Related]
48. Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain.
Reichman C; Singh K; Liu Y; Singh S; Li H; Fajardo JE; Fiser A; Birge RB
Oncogene; 2005 Dec; 24(55):8187-99. PubMed ID: 16158059
[TBL] [Abstract][Full Text] [Related]
49. The roles of Dok family adapters in immunoreceptor signaling.
Mashima R; Hishida Y; Tezuka T; Yamanashi Y
Immunol Rev; 2009 Nov; 232(1):273-85. PubMed ID: 19909370
[TBL] [Abstract][Full Text] [Related]
50. ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines.
Chevalier C; Cannet A; Descamps S; Sirvent A; Simon V; Roche S; Benistant C
PLoS One; 2015; 10(3):e0118854. PubMed ID: 25803821
[TBL] [Abstract][Full Text] [Related]
51. Structural basis for the specific recognition of RET by the Dok1 phosphotyrosine binding domain.
Shi N; Ye S; Bartlam M; Yang M; Wu J; Liu Y; Sun F; Han X; Peng X; Qiang B; Yuan J; Rao Z
J Biol Chem; 2004 Feb; 279(6):4962-9. PubMed ID: 14607833
[TBL] [Abstract][Full Text] [Related]
52. Association of p62, a multifunctional SH2- and SH3-domain-binding protein, with src family tyrosine kinases, Grb2, and phospholipase C gamma-1.
Richard S; Yu D; Blumer KJ; Hausladen D; Olszowy MW; Connelly PA; Shaw AS
Mol Cell Biol; 1995 Jan; 15(1):186-97. PubMed ID: 7799925
[TBL] [Abstract][Full Text] [Related]
53. The substrate specificity of the catalytic domain of Abl plays an important role in directing phosphorylation of the adaptor protein Crk.
Amoui M; Miller WT
Cell Signal; 2000 Oct; 12(9-10):637-43. PubMed ID: 11080615
[TBL] [Abstract][Full Text] [Related]
54. IkappaB kinase beta phosphorylates Dok1 serines in response to TNF, IL-1, or gamma radiation.
Lee S; Andrieu C; Saltel F; Destaing O; Auclair J; Pouchkine V; Michelon J; Salaun B; Kobayashi R; Jurdic P; Kieff ED; Sylla BS
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17416-21. PubMed ID: 15574499
[TBL] [Abstract][Full Text] [Related]
55. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation.
Gishizky ML; Cortez D; Pendergast AM
Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904
[TBL] [Abstract][Full Text] [Related]
56. p130CAS forms a signaling complex with the adapter protein CRKL in hematopoietic cells transformed by the BCR/ABL oncogene.
Salgia R; Pisick E; Sattler M; Li JL; Uemura N; Wong WK; Burky SA; Hirai H; Chen LB; Griffin JD
J Biol Chem; 1996 Oct; 271(41):25198-203. PubMed ID: 8810278
[TBL] [Abstract][Full Text] [Related]
57. Ras complements the carboxyl terminus of v-Abl protein in lymphoid transformation.
Parmar K; Rosenberg N
J Virol; 1996 Feb; 70(2):1009-15. PubMed ID: 8551558
[TBL] [Abstract][Full Text] [Related]
58. Tyrosine phosphorylation of Grb2 by Bcr/Abl and epidermal growth factor receptor: a novel regulatory mechanism for tyrosine kinase signaling.
Li S; Couvillon AD; Brasher BB; Van Etten RA
EMBO J; 2001 Dec; 20(23):6793-804. PubMed ID: 11726515
[TBL] [Abstract][Full Text] [Related]
59. p120-Ras GTPase activating protein (RasGAP): a multi-interacting protein in downstream signaling.
Pamonsinlapatham P; Hadj-Slimane R; Lepelletier Y; Allain B; Toccafondi M; Garbay C; Raynaud F
Biochimie; 2009 Mar; 91(3):320-8. PubMed ID: 19022332
[TBL] [Abstract][Full Text] [Related]
60. JAK-STAT signaling activated by Abl oncogenes.
Danial NN; Rothman P
Oncogene; 2000 May; 19(21):2523-31. PubMed ID: 10851051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
